Multiplex cyclic immunohistochemistry allows in situ detection of multiple markers simultaneously using repeated antigen-antibody incubation, image scanning, and image alignment and integration. Here, we present the operating protocol for identifying immune cell substrates with this technology in lung cancer and paired brain metastasis samples.
The tumor microenvironment involves interactions between host cells, tumor cells, immune cells, stromal cells, and vasculature. Characterizing and spatially organizing immune cell subsets and target proteins are crucial for prognostic and therapeutic purposes. This has led to the development of multiplexed immunohistochemistry staining methods. Multiplex fluorescence immunohistochemistry allows the simultaneous detection of multiple markers, facilitating a comprehensive understanding of cell function and intercellular interactions. In this paper, we describe a workflow for the multiplex cyclic fluorescent immunohistochemistry assay and its application in the quantification analysis of lymphocyte subsets. The multiplex cyclic fluorescent immunohistochemistry staining follows similar steps and reagents as standard immunohistochemistry, involving antigen retrieval, cyclic antibody incubation, and staining on a formalin-fixed paraffin-embedded (FFPE) tissue slide. During the antigen-antibody reaction, a mixture of antibodies from different species is prepared. Conditions, such as antigen retrieval time and antibody concentration, are optimized and validated to increase the signal-to-noise ratio. This technique is reproducible and serves as a valuable tool for immunotherapy research and clinical applications.
Brain metastases (BM) represent the most common central nervous system (CNS) tumors, occurring in nearly half of non-small cell lung cancer cases (NSCLC), with a poor prognosis1. An estimated 10%-20% of NSCLC patients already have BM at the time of initial diagnosis, and approximately 40% of NSCLC cases will develop BM during the course of treatment2. The tumor microenvironment (TME) is closely associated with NSCLC occurrence and BM, including various components, such as blood vessels, fibroblasts, macrophages, extracellular matrix (ECM), lymphoid, bone marrow-derived immune cells, and signaling molecules3,4. Microenvironmental immune cells play a crucial role in influencing cancer cell growth and development. Brain metastases present numerous potential treatment targets characterized by complex immunological microenvironments and signaling processes. For instance, PD-1 inhibitors have shown clinical efficacy for patients with lung cancer brain metastasis (LCBM) as an immune-checkpoint inhibitor (ICI). However, the frequency of responses to PD-1 therapy varies between primary NSCLC and LCBM5, suggesting that the tumor immune microenvironment acts as a critical ICI regulator.
Immunohistochemistry (IHC) is an invaluable tool in the fields of biology, foundation medicine, and pathology6. This detection method visualizes antigen expression through the interaction of antigen-antibody on a tissue slide7. IHC is used for diagnosing predictive markers, evaluating prognostic markers, guiding targeted therapies, and exploring the biological functions of tumor cells8. However, the traditional IHC method can only detect one biomarker at a time. To address this limitation, the innovation of immunohistochemical technology has led to the development of multiplex fluorescence immunohistochemistry (mfIHC), which allows for the simultaneous identification of multiple protein markers on the same tissue slide, both in bright field and fluorescent field9. This advancement provides accurate analysis of cell composition and molecular interactions among stromal cells, immune cells, and cancer cells within the TME.
In this study, we present a protocol for multiplex cyclic immunohistochemistry to analyze the spatial distribution of immune cells. Two primary antibodies of different species, such as rabbit and rat, are chosen for incubation simultaneously, followed by fluorescence-labeled secondary antibodies. Antigen retrieval is performed after each round of antigen-antibody reaction. Autofluorescence is blocked, and 4′, 6-diamidino-2-phenylindole (DAPI) is used for staining the nuclei. The panel includes sequential detection of CD3, CD8, CD20, and CK, cells are categorized according to the markers: tumor cells (CK+), mature T cells (CD3+), cytotoxic T cells (CD3+CD8+), B cells (CD20+)10,11.
The research was approved by the medical ethics committee of Yunnan Cancer Hospital/the Third Affiliated Hospital of Kunming Medical University. All the subjects/legal guardians signed informed consent.
1. Slide preparation
2. Heat-induced epitope retrieval (HIER)
3. Peroxidase blocking
4. Primary antibody incubation for first round
5. Secondary antibody incubation for first round
6. Heat-induced epitope retrieval and peroxidase blocking
7. Primary antibody incubation for second round
8. Secondary antibody incubation for second round
9. Autofluorescence quenching and DAPI staining
10. Slide scanning
11. Quantitative evaluation of cell densities
We present a protocol for cyclic antigen detection using 5-color multiplex fluorescence on a single slide. Through our optimization of the assay, we enable the incubation of two antibodies from different species (Figure 1). The necessary devices for the experiment procedure include a pressure cooker and immunostaining box (Figure 2A).
After completing the assay, we define pseudo color of the four markers before scanning the slides. The pseudo colors of CD3, CD8, CD20 and CK are yellow, red, green, and cyan, respectively. The nuclei are labeled with DAPI. Representative regions of tumor and stroma are selected for analysis. Fluorescent spectrum at 495 nm, 578 nm, 652 nm, and 590 nm are captured using 3D automatic digital slide scanner. A representative stack image and single-labeled images in lung cancer brain metastases tissue are shown in Figure 2B. Based on images containing single marker fluorescence signal, the scanner software extracted cell phenotype characteristics based on pseudo color. Corresponding numbers of positive immune cells and total immune cells were counted as well. Each stained protein levels are quantified in the detected tissues by calculating H-score12. After these procedures, the number of each tumor-infiltrating lymphocytes type and the proportion of each cell type in the total number of target cells are counted and analyzed. The proportion of each immune cell type presents the effective percentage of tumor-infiltrating lymphocytes. The percentage of CD3+, CD3+CD8+ T cells and CD20+ B cells was analyzed in lung cancer brain metastases compared to primary lung cancer sections. Representative results are shown in Figure 3. The density of immune cells (CD3+ T cells, CD3+ CD8+ T cells) is lower in lung cancer brain metastases than primary lung cancer. CD20+ B cells are higher in the brain metastasis group than the primary lung cancer group. However, the results are not different significantly between these two groups for the limited samples.
Figure 1: Workflow of multiplex cyclic fluorescence immunohistochemistry staining. The 4 µm sections are cut and adhered on adhesive slide. The following operating steps are performed: deparaffinization and rehydration, antigen retrieval, antigen retrieval, antigen blocking, primary antibody mixture incubation, secondary antibody incubation, then repeating the steps of antigen retrieval, antigen blocking, primary antibody mixture incubation and secondary antibody incubation, followed by reducing autofluorescence, selecting the appropriate filter for slide scanning and analyzing the results. Please click here to view a larger version of this figure.
Figure 2: Operation methods of multiplex fluorescence immunohistochemistry staining. Antigen treatment is performed by heating sections in a pressure cooker. (A) The pressure cooker is used for Heat-induced epitope retrieval. In the process of antibody incubation, the slides are placed in the immunostaining box. (B) Representative composite and single-stained images for the panel used in lung cancer brain metastases tissue. Please click here to view a larger version of this figure.
Figure 3: Immune cells proportion within primary lung cancer and lung cancer brain metastases. CD3+, CD3+CD8+, CD20+ immune cells proportion in four lung cancer brain metastases tissues are lower than paired primary lung cancer tissues (error bars: Standard deviation). Please click here to view a larger version of this figure.
We have described the process for multiplex cyclic fluorescence immunohistochemistry staining. The primary antibody selection is a crucial aspect of the fluorescence immunohistochemistry assay, and monoclonal antibodies are recommended for better specificity and repeatability. To optimize the working concentration of the primary antibody, a series of dilutions have been tested through immunohistochemistry experiments. Both positive controls (to assess target antigen expression) and negative controls (no primary antibody incubation) are essential and should be set up.
In this protocol, the primary antibodies are diluted and prepared for a mixture from different species. The fluorescence-labeled secondary antibodies are also pooled and incubated in the same way, derived from different species. So, the critical step is choosing the species for different primary antibodies based on the antigens, and the monoclonal antibody is preferred compared with polyclonal antibody. These can ensure that the combination between primary antibody and secondary antibody is specific. The mixed liquid should achieve the working concentration for both primary antibodies and cross-reactivity should not exist between the two antibodies simultaneously. If the primary antibodies are of the same species, one secondary antibody is incubated first, then the second one. When determining the sequence of primary antibody incubation in a panel, priority should be given to antibodies that are sensitive to the antigen-antibody reaction, for the low expression antigens, the intensity would strengthen during second epitope retrieval. Before the second round of antibody incubation, repeating antigen retrieval takes less time (1 min) compared to the first operation (2 min). The fluorescence intensity from previous cyclic staining will not decrease even though the sections undergo heat-induced retrieval twice. For avoiding non-specific immunoreactivity, the incubation conditions need to be optimized including antibody working concentration, incubation time, and environmental temperature.
Various methods of epitope retrieval have been developed in recent decades, primarily divided into heat-induced epitope retrieval (HIER) and protease-induced epitope retrieval (PIER). Heating is an efficient antigen retrieval method that exposes antigen epitopes, making them more effectively detected by antibodies13. The two main options for antigen retrieval are based on citrate buffer and high pH EDTA buffer14. The optimized retrieval condition is identified according to the target antigen.
Autofluorescence can interfere with fluorescent imaging on sections caused by endogenous fluorophores and reagents used in tissue processing15. The use of an associated reagent is required for elution. Fluorophores are selected with emission peaks avoiding autofluorescence peaks (around 490 nm)16,17. Sudan Black B and NaBH4 have been reported for quenching tissue autofluorescence18,19. The combination of Sudan Black B and NaBH4 reduced fluorescence background in targeted renal formalin-fixed paraffin-embedded tissue20. In this protocol, the tissue treatment of KMnO4 in a concentration of 0.15 M/L is time saving for 1 min. KMnO4 covers a layer on the tissue for shielding spontaneous fluorescence and reduces background fluorescence, the specific staining of detected protein is more visualized.
The whole slides are scanned in four different filters channels, image alignment analysis is necessary, it is a great challenge to align the localization of single-cell and subcellular structures. For multispectral images from this technique, professional light imaging equipment and quantitative analysis software are needed for avoiding spectral crosstalk. The expensive cost of the instrument limits its application. Co-incubation of two antibodies saves time, especially when dealing with a 6-marker panel, which requires 3 cycles of incubation. This technique is used to visualize more detailed characterization of immune cells in tumor immune microenvironments. In future, the method will be applied for quantitative analysis of tumor-associated tertiary lymphoid structures.
In summary, multiplex cyclic fluorescence immunohistochemistry enables multiple targets to be stained by individually labeled fluorophores on a single slide. This assay provides an improved understanding of the spatial distribution of cells in the tumor immune microenvironment, and the spatial proximity of tumor-immune cells contributes to screening patients who will benefit from immunotherapy.
The authors have nothing to disclose.
This work was supported by the National Natural Science Foundation of China (NO.81860413, 81960455), Yunnan Science and Technology Department Fund (202001AY070001-080), Scientific Research Foundation of Education Department of Yunnan Province(2019J1274).
0.15 mol/L KmnO4 | Maixin Biotechnology Co. Ltd. | MST-8005 | |
100x sodium citrate | Maixin Biotechnology Co., Ltd | MVS-0100 | |
3% hydrogen peroxide | Maixin Biotechnology Co., Ltd | SP KIT-A1 | |
3D Pannoramic MIDI | 3D histech Ltd | Pannoramic MIDI 1.18 | |
Alexa Fluor 488 | Abcam | ab150113 | |
Alexa Fluor 568 | Abcam | ab175701 | |
Alexa Fluor 594 | Abcam | ab150116 | |
Alexa Fluor 647 | Abcam | ab150079 | |
Bond primary antibody diluent | Lecia | AR9352 | |
CD20 | Maixin Biotechnology Co., Ltd | kit-0001 | |
CD3 | Maixin Biotechnology Co., Ltd. | kit-0003 | |
CD8 | Maixin Biotechnology Co., Ltd | RMA-0514 | |
CK | Maixin Biotechnology Co. Ltd. | MAB-0671, | |
DAPI | sig-ma | D8417 | |
ethanol | Sinopharm Group Chemical reagent Co., LTD | 10009218 | |
Histocore Multicut | lecia | 2245 | |
PBS(powder) | Maixin Biotechnology Co., Ltd | PBS-0061 | |
slide viwer | 3D histech Ltd | ||
xylene | Sinopharm Group Chemical reagent Co., LTD | 10023418 |